AGLE - Aeglea BioTherapeutics, Inc.
| Previous Close | 8.78 |
| Open | 8.85 |
| Bid | 5.15 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 8.81 - 9.25 |
| 52 Week Range | 2.81 - 12.00 |
| Volume | 210,511 |
| Avg. Volume | 318,639 |
| Market Cap | 199.79M |
| Beta | 0.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.82 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.33 |
- GlobeNewswire•20 hours ago
Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the appointment of Bryan Lawlis, Ph.D., to its Board of Directors, effective immediately. “We are delighted to welcome Dr. Lawlis to our Board, Bryan is a seasoned biotechnology industry executive who brings a tremendous amount of manufacturing and process development expertise,” said Anthony G. Quinn, M.B Ch.B, Ph.D., interim chief executive officer of Aeglea.
- Zacks•14 days ago
Alkermes' Aristada Initio Approved by FDA for Schizophrenia
FDA approves Alkermes' (ALKS) Aristada Initio (aripiprazole lauroxil) for the treatment of schizophrenia in adults.
- GlobeNewswire•17 days ago
Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that the Compensation Committee of its Board of Directors has granted non-qualified stock options to purchase an aggregate of 49,500 shares of Aeglea’s common stock to four new employees under Aeglea’s 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aeglea (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Aeglea, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
- Zacks•22 days ago
Novo Nordisk (NVO) Announces Results in Diabetes Studies
Novo Nordisk (NVO) announces results from a number of studies being evaluated to treat diabetes.
- Zacks•25 days ago
Anika Reports Top Line Data from CINGAL Study, Shares Slump
Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee.
- Zacks•26 days ago
Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.
- Zacks•26 days ago
Alexion (ALXN) Submits Application for ALXN1210 with FDA
Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).
- Zacks•27 days ago
Agios (AGIO) Initiates Phase III Study on PK Deficiency Drug
Agios Pharmaceuticals, Inc. (AGIO), initiates a phase III ACTIVATE study which will evaluateits lead rare genetic diseases candidate, AG-348 in patients with PK deficiency who do not receive regular blood transfusions.
- Zacks•last month
Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone
Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.
- Zacks•last month
Flex Pharma Down on Workforce Reduction, Ends Phase II Study
Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.
- Zacks•last month
Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA
Roche (RHHBY) announced that the FDA has approved the label expansion for its oncology drug Avastin in combination with chemotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.
- Benzinga•last month
BMO: Aeglea Has A Potentially Market-Conquering Arginase Deficiency Candidate, Oncology Opportunity
Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) hasn’t received much attention in its two years on the market, but on Thursday it caught the eye of its fourth analyst and fourth bull. The Rating BMO Capital ...
- InvestorPlace•2 months ago
5 Biotech Stocks to Boost Your Portfolio’s Health This Year
Also, a slowdown in sales of some of the most high-profile older drugs, courtesy of payers and competitive pressure from both branded and generic drugs, is a concern for the sector. Drug pricing has been in the spotlight once again this month when President Donald Trump announced plans to lower prescription drug costs.
- GlobeNewswire•2 months ago
Aeglea BioTherapeutics to Present at UBS Global Healthcare Conference
AUSTIN, Texas, May 15, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- Associated Press•2 months ago
Aeglea: 1Q Earnings Snapshot
On a per-share basis, the Austin, Texas-based company said it had a loss of 49 cents. The biopharmaceutical company posted revenue of $1.5 million in the period. Aeglea shares have increased 83 percent ...
- GlobeNewswire•2 months ago
Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results
AUSTIN, Texas, May 08, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- GlobeNewswire•3 months ago
Aeglea BioTherapeutics Prices Public Offering of Common Stock
AUSTIN, Texas, April 18, 2018-- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases ...
- Zacks•3 months ago
Aeglea Initiates Lung Cancer Combination Study With Keytruda
Aeglea BioTherapeutics (AGLE) doses first patients in two early stage lung cancer studies evaluating pegzilarginase as single agent and in combination with Merck's Keytruda.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of AGLE earnings conference call or presentation 13-Mar-18 12:00pm GMT
Q4 2017 Aeglea Bio Therapeutics Inc Earnings Call
